Evaluation of the Usefulness of Pre-operative Exemestane (EXE) Therapy for Treatment of Hormone-Sensitive Breast Cancer in Postmenopausal Patients, and EXE + TC Combination Therapy for Nonresponders to EXE Therapy. (JBCRG-11TC).

Trial Profile

Evaluation of the Usefulness of Pre-operative Exemestane (EXE) Therapy for Treatment of Hormone-Sensitive Breast Cancer in Postmenopausal Patients, and EXE + TC Combination Therapy for Nonresponders to EXE Therapy. (JBCRG-11TC).

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Jun 2016

At a glance

  • Drugs Exemestane (Primary) ; Cyclophosphamide; Docetaxel
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Jun 2016 Status changed from recruiting to active, no longer recruiting.
    • 19 Jun 2014 Planned End Date changed from 30 Sep 2023 to 31 Mar 2026 as reported by University Hospital Medical Information Network - Japan.
    • 18 Jun 2013 Planned End Date added to 30 Sep 2023 as reported by University Hospital Medical Information Network - Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top